<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741323</url>
  </required_header>
  <id_info>
    <org_study_id>HIVTR-CCR5</org_study_id>
    <secondary_id>20730</secondary_id>
    <nct_id>NCT02741323</nct_id>
  </id_info>
  <brief_title>Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients</brief_title>
  <official_title>Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maraviroc (MVC) is a type of HIV medicine called a CCR5 inhibitor. This study will evaluate&#xD;
      the safety and tolerability of MVC in HIV-infected adults receiving a kidney transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MVC is a CCR5 inhibitor that may have a positive role in modulating the immune response&#xD;
      following transplantation. The purpose of this study is to evaluate the safety and&#xD;
      tolerability of MVC in HIV-infected adults in need of a kidney transplant. The study will&#xD;
      also evaluate whether using both immunosuppressant drugs and MVC will improve kidney function&#xD;
      after a kidney transplant.&#xD;
&#xD;
      This study will enroll HIV-infected adults on combination antiretroviral therapy (cART) who&#xD;
      need a kidney transplant. At the time of their kidney transplant, study participants will be&#xD;
      randomly assigned to receive either MVC or placebo as an addition to their cART regimen. (MVC&#xD;
      or placebo will be provided by the study. However, the HIV medicines in their cART regimens&#xD;
      will not be provided by the study.) Participants will receive MVC or placebo throughout their&#xD;
      participation in the study, which will be 1 to 3 years depending on when they enroll in the&#xD;
      study.&#xD;
&#xD;
      Study visits will occur at enrollment (Day 0) and post-transplant Weeks 1, 2, 4, 8, 13, 26,&#xD;
      39, 52, 78, 104, 130, and 156. Study visits may include a physical examination, blood&#xD;
      collection, lymph node collection, urine sample collection, and a kidney biopsy. During the&#xD;
      study, participants will also be monitored closely for evidence of drug toxicities, HIV&#xD;
      treatment failure and rejection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measured glomerular filtration rate by iohexol clearance</measure>
    <time_frame>Measured at Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with graft loss, Grade 3 or greater toxicities, and/or permanent treatment discontinuations</measure>
    <time_frame>Measured through Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean CD45 gene expression count (PTPRC)</measure>
    <time_frame>Measured through Week 26</time_frame>
    <description>Based on the formalin-fixed paraffin-embedded (FFPE) kidney biopsy sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean CD45 quantitative immunohistochemistry (IHC)</measure>
    <time_frame>Measured through Week 26</time_frame>
    <description>Based on FFPE sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean tCRM score</measure>
    <time_frame>Measured through Week 26</time_frame>
    <description>Using the 11-gene tCRM module on FFPE biopsy shaves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean uCRM score</measure>
    <time_frame>Measured through Week 26</time_frame>
    <description>Using the 11-gene uCRM module on urine cell pellets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean uCRM score</measure>
    <time_frame>Measured through Week 52</time_frame>
    <description>Using the 11-gene uCRM module on urine cell pellets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m^2</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
    <description>Measured by chronic kidney disease epidemiology collaboration equation (CKD-EPI), cystatin C, and chronic kidney disease (CKD)-cystatin C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with defined CKD stage 4 or 5</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean eGFR</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
    <description>Calculated by CKD-EPI, cystatin C, and CKD-cystatin C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the slope of eGFR</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
    <description>Calculated by CKD-EPI, cystatin C, and CKD-cystatin C variable models over time based on serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV reactivation (frequency of CD4+ T cells producing HIV multiply spliced RNAs upon T-cell receptor stimulation [TCR] stimulation)</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV DNA in peripheral blood CD4+ T cells</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV RNA in peripheral blood CD4+ T cells</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV RNA levels (single copy assay)</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically suspected and biopsy proven acute rejection</measure>
    <time_frame>Measured through Week 156</time_frame>
    <description>Defined by histologic evidence of rejection and graft dysfunction as identified on central read of biopsy slides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute cellular rejection grade equal to or greater than IA</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
    <description>Measured by the Banff 2007 criteria as identified on central read of biopsy slides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of first and highest grade of acute cellular rejection</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibody mediated rejection</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of de novo anti-donor human leukocyte antigen (HLA) antibodies</measure>
    <time_frame>Measured at Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology/in situ hybridization to assess HIV infection in the renal allograft</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft loss</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all adverse events (AEs) greater than or equal to Grade 3</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs) greater than or equal to Grade 3</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of opportunistic infections or neoplasms</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-opportunistic infections requiring hospitalization or systemic therapy</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcineurin inhibitor trough levels for participants on maraviroc versus placebo</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcineurin inhibitor AUC for participants on maraviroc versus placebo</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of CCR5 blockade (maraviroc)</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough levels of CCR5 blockade (maraviroc)</measure>
    <time_frame>Measured through participants' last study visit, which will be during Years 1 to 3, depending on when they enroll in the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>HIV Infections</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Arm 1: Maraviroc (MVC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MVC at the time of admission for transplantation and prior to transplant. Participants will receive MVC throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at the time of admission for transplantation and prior to transplant. Participants will receive placebo throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR &lt; 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).&#xD;
Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability.</description>
    <arm_group_label>Arm 1: Maraviroc (MVC)</arm_group_label>
    <other_name>MVC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR &lt; 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).&#xD;
Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability.</description>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is able to understand and provide informed consent.&#xD;
&#xD;
          -  Documented HIV infection (by any licensed enzyme-linked immunosorbent assay [ELISA]&#xD;
             and confirmation by Western Blot, positive HIV antibody (ab) indirect fluorescent&#xD;
             antibody (IFA), or documented history of detectable HIV-1 RNA).&#xD;
&#xD;
          -  Participant is 18 years of age or older.&#xD;
&#xD;
          -  CD4+ T-cell count greater than or equal to 200/ÂµL at any time in the 26 weeks prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Most recent HIV-1 RNA less than 50 copies RNA/mL. Eligibility at the time of&#xD;
             enrollment will be determined based on the most recent HIV-1 RNA, not more than 26&#xD;
             weeks prior to enrollment. Subjects who require a switch in combination antiretroviral&#xD;
             therapy (cART) regimen to become study eligible must also have an eligible HIV-1 RNA&#xD;
             result post change in cART.&#xD;
&#xD;
          -  Participant meets standard listing criteria for placement on transplant waiting list.&#xD;
&#xD;
          -  For participants with an HIV+ deceased donor:&#xD;
&#xD;
               -  No active opportunistic infections.&#xD;
&#xD;
               -  Concurrence by the study team that based on medical history and ART, viral&#xD;
                  suppression can be achieved in the recipient post-transplant.&#xD;
&#xD;
               -  Must be enrolled in an Institutional Review Board (IRB) approved research&#xD;
                  protocol that fulfills the requirements of the DHHA Hope Act Policy (see the&#xD;
                  protocol for more information).&#xD;
&#xD;
               -  HIV+ deceased donor must have no evidence of invasive opportunistic complications&#xD;
                  of HIV infection, and must have a pre-implant biopsy.&#xD;
&#xD;
          -  Antiretroviral (ARV) Use: Participant is on a stable cART regimen for at least 3&#xD;
             months prior to enrollment (unless changes are made due to toxicity, drug&#xD;
             interactions, convenience or to an eligible non-protease inhibitor-based regimen).&#xD;
             Switch should not be due to virologic failure. A regimen consisting of 2 NTRTIs and an&#xD;
             integrase inhibitor is preferred due to minimal drug interaction but any non-protease&#xD;
             inhibitor regimen may be used.&#xD;
&#xD;
               -  If on a protease inhibitor based regimen, participant must be switched to a&#xD;
                  non-protease inhibitor-based regimen based on lack of any prior drug resistance&#xD;
                  or antiretroviral-treatment failure, and be willing to remain on indefinitely&#xD;
                  unless a change is medically necessary. Participants who need to be switched must&#xD;
                  have been on a stable cART regimen for at least 3 months prior, and must have an&#xD;
                  eligible HIV-1 RNA result post change in cART.&#xD;
&#xD;
               -  If already on a stable non-protease inhibitor-based regimen, participant is&#xD;
                  willing to remain on this regimen indefinitely unless a change in regimen is&#xD;
                  medically indicated.&#xD;
&#xD;
               -  If untreated, must initiate and be willing to remain on indefinitely a&#xD;
                  non-protease inhibitor-based antiretroviral regimen unless a change is medically&#xD;
                  necessary.&#xD;
&#xD;
          -  No known allergy or intolerance to components of maraviroc (MVC) or its formulation.&#xD;
&#xD;
          -  No known contraindication to MVC.&#xD;
&#xD;
          -  Female participants of child-bearing potential must have a negative serum beta-human&#xD;
             chorionic gonadotropin (HCG) pregnancy test within 30 days of randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is currently on MVC.&#xD;
&#xD;
          -  Participant needs multi-organ transplant.&#xD;
&#xD;
          -  Participant has a live donor who is HIV+.&#xD;
&#xD;
          -  Participant is unable to switch to a non-protease inhibitor-based cART regimen.&#xD;
&#xD;
          -  Participant has received immunosuppressant medication in the 6 months prior to&#xD;
             enrollment. Note: Low dose maintenance steroids (less than or equal to 10 mg per day&#xD;
             of prednisone, or equivalent strength steroid) will not be considered&#xD;
             immunosuppression.&#xD;
&#xD;
          -  Opportunistic Complication History: Any history of progressive multifocal&#xD;
             leukoencephalopathy (PML), chronic intestinal cryptosporidiosis of greater than 1&#xD;
             month duration, or primary central nervous system (CNS) lymphoma. Note: History of&#xD;
             pulmonary coccidiodomycosis will be treated per local site policy regarding this&#xD;
             infection in HIV negative transplant candidates, generally requiring a 5-year&#xD;
             disease-free interval.&#xD;
&#xD;
          -  Participant has a history of any neoplasm except for the following: resolved kaposi's&#xD;
             sarcoma, in situ anogenital carcinoma, adequately treated basal or squamous cell&#xD;
             carcinoma of the skin, solid tumors (except primary CNS lymphoma) treated with&#xD;
             curative therapy and disease free for more than 5 years. History of renal cell&#xD;
             carcinoma requires disease-free state for 2 years. History of leukemia and&#xD;
             disease-free duration will be per site policy.&#xD;
&#xD;
          -  Substance use that in the opinion of the investigator would interfere with compliance&#xD;
             with the study requirements.&#xD;
&#xD;
          -  Participant is pregnant or breastfeeding. Note: Participants who become pregnant&#xD;
             post-transplant will continue to be followed in the study and will be managed per&#xD;
             local site practice. Women that become pregnant should not breastfeed.&#xD;
&#xD;
          -  Participant has used interleukin-2 (IL-2) or granulocyte-macrophage colony-stimulating&#xD;
             factor (GM-CSF) in the prior six months.&#xD;
&#xD;
          -  Participant has received interferon-alpha therapy in the prior 12 weeks.&#xD;
&#xD;
          -  Use of investigational drugs within 4 weeks of enrollment.&#xD;
&#xD;
          -  Past or current medical problems or findings from medical history, physical&#xD;
             examination, or laboratory testing that are not listed above, which, in the opinion of&#xD;
             the investigator, may pose additional risks from participation in the study, may&#xD;
             interfere with the participant's ability to comply with study requirements, or that&#xD;
             may impact the quality or interpretation of the data obtained from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Stock, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB HIVTR-CCR5 Non-Network CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-2060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA HIVTR-CCR5 Non-Network CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF HIVTR-CCR5 Non-network CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown HIVTR-CCR5 Non-Network CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory HIVTR-CCR5 Non-Network CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern HIVTR-CCR5 Non-Network CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Maryland HIVTR-CCR5 Non-Network CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JHU HIVTR-CCR5 Non-Network CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Med. Ctr. HIVTR-CCR5 Non-Network CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Penn HIVTR-CCR5 Non-network CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-infected with end-stage kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

